New Staging System for Colorectal Cancer Patients with Synchronous Peritoneal Metastasis in Accordance with the Japanese Classification of Colorectal Carcinoma: A Multi-Institutional Study

Noura, Shingo; Ohue, Masayuki; Ito, Yuri; Miyoshi, Norikatsu; Kobayashi, Hirotoshi; Kotake, Kenjiro; Sugihara, Kenichi
February 2016
Digestive Surgery;Feb2016, Vol. 33 Issue 1, p66
Academic Journal
Background: Peritoneal metastasis of colorectal cancer (CRC) is often discovered during initial surgery. The aim of this study is to propose a new staging system that could be used to help determine the management of CRC patients. Methods: We evaluated a total of 766 Stage IV CRC patients with synchronous peritoneal metastasis. According to the Japanese classification, we divided the peritoneal metastasis into P1, P2, and P3. We distinguished distant metastasis from liver metastasis and peritoneal metastasis. According to the Cox proportional hazard model, we constructed a new staging group. Results: According to a comparison of the R2 statistics, the combination of liver metastasis and peritoneal metastasis was selected as the final variables. Next, we defined P1H(-) as Grade A, P2H(-) as Grade B, and other groups as Grade C. Our proposed new stage (Akaike Information Criteria [AIC] 7,338.82; concordance index [c-index] 0.644; R2 0.123) could thus divide the patients into different prognostic groups more clearly than the current Japanese classification (AIC 7,373.89; c-index 0.619; R2 0.097). Conclusion: Our proposed new staging system is very simple and easy for general surgeons to follow. This system is useful for determining the appropriate operative strategy for CRC patients with peritoneal metastasis and for estimating the patients' prognosis. © 2015 S. Karger AG, Basel


Related Articles

  • Ziv-aflibercept yields encouraging results in metastatic colorectal cancer.  // Hem/Onc Today;11/10/2012, Vol. 13 Issue 21, p26 

    The article reports on a study by Doctor Eric Van Cutsem, head of digestive oncology and professor of medicine at University Hospital Gasthuisberg in Leuven, Belgium, stating that the addition of ziv-aflibercept to infusional FOLFIRI improved survival in metastatic colorectal cancer patients.

  • Immune Architecture of Colorectal Lung Metastases and Implications for Patient Survival. Brunner, Stefan M.; Hahn, Ulrich; Jeiter, Tonia; Kesselring, Rebecca; Rubner, Christoph; Ruemmele, Petra; Sziklavari, Zsolt; Hofmann, Hans S.; Schlitt, Hans J.; Fichtner-Feigl, Stefan // European Surgical Research;Nov2016, Vol. 57 Issue 3/4, p186 

    Background: Pulmonary metastases occur in 10-20% of patients with colorectal cancer and significantly influence long-term survival. In this study, the immunological architecture of colorectal lung in comparison to liver metastases and its impact on patient survival were examined. Methods:...

  • Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. Tang, Ronald; Kain, Tatiana; Herman, June; Seery, Tara // Cancer Management & Research;Nov2015, Vol. 7, p357 

    Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer. Since this time, however, few case reports outlining real-world usage have been published in the literature. Here, we...

  • Survival Impact of Extracolorectal Malignancies in Colorectal Cancer Patients. Kawai, Kazushige; Ishihara, Soichiro; Nozawa, Hiroaki; Hata, Keisuke; Kiyomatsu, Tomomichi; Tanaka, Toshiaki; Nishikawa, Takeshi; Otani, Kensuke; Yasuda, Koji; Murono, Koji; Sasaki, Kazuhito; Watanabe, Toshiaki // Digestion;Oct2016, Vol. 94 Issue 2, p92 

    Background/Aims: Colorectal cancer (CRC) patients are at high risk for developing extracolorectal malignancies (EMs). Although development of a second primary cancer and deaths thereof are included as events of disease-free survival (DFS) and overall survival (OS), the role of EMs in these...

  • Bone metastasis predicts poor prognosis of patients with brain metastases from colorectal carcinoma post aggressive treatment. Duan, Hao; He, Zhen-Qiang; Guo, Cheng-Cheng; Li, Jue-Hui; Wang, Jian; Zhu, Zhe; Sai, Ke; Chen, Zhong-Ping; Jiang, Xiao-Bing; Mou, Yong-Gao // Cancer Management & Research;Aug2018, Vol. 10, p2467 

    Purpose: The presence of brain metastasis (BM) in patients with colorectal cancer (CRC) is usually associated with terminal-stage illness; however, a subgroup of patients receiving aggressive treatment can have a satisfactory prognosis. This study was designed to investigate the profile of...

  • Kolorektal Kanserlerde Lenf Nodu Oranının Prognostik Önemi. Özdemir, Yavuz; Özdemir, Sevim; Filiz, Ali İlker; Sücüllü, İlker; Kurt, Yavuz; Yıldız, Mehmet // Balkan Medical Journal;Mar2011, Vol. 28 Issue 1, p86 

    Objective: This study was designed to assess the prognostic value of lymph node ratio (LNR) in patients with nonmetastatic colorectal cancer treated with radical resection. Material and Methods: The characteristic and pathologic parameters of 280 patients operated on for nonmetastatic colorectal...

  • Two-stage laparoscopic liver resection for bilateral colorectal liver metastasis. Machado, M. A.; Makdissi, F. F.; Surjan, R. C.; Kappaz, G. T.; Yamaguchi, N. // Surgical Endoscopy;Aug2010, Vol. 24 Issue 8, p2044 

    Hepatectomy may prolong the survival of colorectal cancer patients with liver metastases. Two-stage liver surgery is a valid option for the treatment of bilobar colorectal liver metastasis. This video demonstrates technical aspects of a two-stage pure laparoscopic hepatectomy for bilateral liver...

  • Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer. Morita, Sachi; Uehara, Keisuke; Nakayama, Goro; Shibata, Takashi; Oguri, Tomoyo; Inada-Inoue, Megumi; Shimokata, Tomoya; Sugishita, Mihoko; Mitsuma, Ayako; Ando, Yuichi // Cancer Chemotherapy & Pharmacology;Feb2013, Vol. 71 Issue 2, p405 

    Purpose: Bevacizumab, a monoclonal antibody that binds to VEGF, has a well-known toxic effect of hypertension. We studied possible associations between bevacizumab-related hypertension and gene polymorphisms to assure safer cancer therapy. Methods: We retrospectively studied 60 Japanese patients...

  • Discovery of molecular determinants of response to targeted therapies in colorectal cancer using patient-derived xenografts ('xenopatients'). Sassi, Francesco; Migliardi, Giorgia; Zanella, Eugenia; Galimi, Francesco; Cottino, Francesca; Bertotti, Andrea; Trusolino, Livio // BMC Proceedings;2013, Vol. 7 Issue Suppl 2, p1 

    The article focuses on the molecular determinants of response to the targeted therapies associated with the colorectal cancer, using patient-derived xenografts. It mentions that only few patients suffering from metastatic colorectal cancer (mCRC) get clinical benefit from therapy with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics